BRINGING CLARITY
TO PATIENT CARE

Klaris will enable fast, targeted treatment for life-threatening infections.

THE PROBLEM

Appropriate antibiotic therapy is the biggest difference between life and death for patients hospitalized with serious bacterial infections, yet half of all patients who are administered antibiotics in the hospital are treated inappropriately.

Antibiotic selection is particularly difficult for these patients because doctors must act days before lab results can reveal the best treatment path.  Furthermore, rising antibiotic resistance increasingly complicates antibiotic selection since it reduces the number of antibiotics that can effectively cure the patient.

50

of all patients who are administered antibiotics in the hospital are treated inappropriately

Source: Marquet K., Liesenborgs A., Bergs J., Vleguls A., Claes N., Critical Care (2015) 19:63.

ENABLING FIRST-LINE ANTIBIOTIC SUCCESS

Current lab tests take days to complete because they rely on the time-consuming growth and average response of millions of bacteria to the antibiotics being considered for treatment.

Our proprietary single-cell analysis technology shortens test time by “zooming in” and measuring the live response of each pathogenic cell directly, thus bypassing the need for time-consuming culture steps.

Furthermore, the same method is able to simultaneously identify the pathogens whose response is being evaluated, allowing us to deliver pathogen identification (ID) and antibiotic susceptibility test (AST) results together within four hours.

CURRENT APPROACHES

THE LIMITS OF GENETIC TECHNOLOGY

One of the hopes for the genetic revolution was the development of diagnostic tests that could be used to reliably guide therapy for diseases such as pneumonia. Due to the dynamic complexity of cellular physiology at both the molecular and systems level, this approach has not been as successful as hoped.  As such, hospitals must still rely on slow, century-old technology in order to determine which antibiotics will be effective against an infection.  

OUR APPROACH

FINDING A BETTER WAY

Klaris was founded on the insight that, by avoiding reductionist assumptions and instead focusing on functional effects, in vitro diagnostics will be better able to predict clinical success for bacterial infections.  Relying on functional effects also allows diagnostic tests to stay ahead of emerging antibiotic resistance patterns because clinical relevance persists even as bacteria evolve new resistance mechanisms.

ACCURATE AND COMPREHENSIVE TESTING

At Klaris, we believe that the more relevant a diagnostic system is to the disease physiology, the better it will be able to predict clinical success.  Our patent-pending technology relies on measuring functional endpoints that translate directly to the desired clinical response, enabling us to accurately predict antibiotic success for all major infections.  Furthermore, pathogens are classified according to clinical standards, allowing for complete AST interpretation within a single platform.  

PHENOTYPIC

Measuring the phenotypic bacterial response to antibiotics ensures that the clinical validity of the current gold standard is maintained for rapid testing.

MULTIPLEXED

Comprehensive pathogen coverage permits symptom-based testing, meaning few assumptions are required about the pathogens causing the infection.

QUANTITATIVE

Quantification at single-cell resolution enables a detailed understanding of the microbial distribution within a patient sample, which is critical for diagnosing complex infections.

Single-cell Biometric Analysis

Klaris uses deep neural networks to recognize the unique “biometric fingerprint” produced by different bacterial species encapsulated within microfluidic droplets.  Pathogen identification and antibiotic susceptibility are seamlessly integrated because they are accomplished using the same method, reducing test cost and complexity.  Furthermore, since we only deal with live cells, minimal processing of the patient specimen is required.  The result is market-leading AST times at comparable cost to the standard of care.

LIFTING DIAGNOSTICS TO NEW HEIGHTS

Klaris will redefine patient care by developing a new generation of diagnostics that will help doctors safely cure serious infections.

Learn More